Mutated IDH1 is an oncogenic driver that occurs in up to 16% of AML patients and is an actionable target for treatment.1
NeoGenomics has partnered with Servier to offer eligible AML patients a rapid IDH1/2 test by PCR with a 3-5 day turnaround time to help guide your treatment decisions. As part of this program, eligible AML patients have access to rapid IDH1/2 testing at no additional cost. Identifying these mutations early can provide critical insights into the disease's progression and and help identify new therapies that could improve patient outcomes.
Personalize your AML treatment plan with rapid IDH1 testing from NeoGenomics
IDHNow for AML Sponsored Testing Program
For AML patients, time is of the essence. Rapid PCR testing makes personalized treatment possible for patients with AML. To support physicians in determining their patient’s IDH1/2 mutation status, Servier is sponsoring a testing program for eligible patients at no additional cost. Get IDHNow for AML to inform treatment decisions.
Patient eligibility criteria:
- Patient has newly diagnosed AML, not previously treated
- Patient does not have a known IDH1 mutation from a previous test
- Patient lives and receives treatment in the United States or a US territory
- Patient has not previously been tested under this Program
IDHNow for AML will be run on PCR and results will be provided in 3-5 days
Resources
References: 1. Zarnegar-Lumley S, Alonzo TA, Gerbing RB, et al. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood Advances. 2023;7(19):5941-5953. doi:10.1182/bloodadvances.2022008282
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients